Medicus Pharma (MDCX) Total Current Liabilities (2023 - 2026)
Medicus Pharma's (MDCX) quarterly Total Current Liabilities came in at $9.9 million in Q4 2025, up 330.92% YoY from $2.3 million in Q4 2024, and down 6.75% on a QoQ basis from $10.7 million in Q3 2025.
Medicus Pharma (MDCX) Total Current Liabilities (2023 - 2026) Analysis & Trends
Medicus Pharma (MDCX) has 3 years of Total Current Liabilities data on file, last reported at $9.9 million in Q4 2025.
- Quarterly Total Current Liabilities rose 330.92% year-over-year to $9.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.9 million (up 330.92% YoY) and the FY2025 annual result came in at $9.9 million, up 330.92% from the prior year.
- Total Current Liabilities declined to $9.9 million in Q4 2025, from $10.7 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $10.7 million in Q3 2025 to a low of $781609.0 in Q4 2023.
- A 3-year average of $5.9 million and a median of $5.9 million in 2025 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Current Liabilities surged 195.06% — and 2025, when it surged 330.92%.
- Tracing MDCX's Total Current Liabilities over 3 years: stood at $781609.0 in 2023, then jumped by 195.06% to $2.3 million in 2024, then surged by 330.92% to $9.9 million in 2025.
- The last three Total Current Liabilities figures came in at $9.9 million (Q4 2025), $10.7 million (Q3 2025), and $8.5 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 54.90 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 41.64 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 27.73 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 31.75 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 31.55 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 25.50 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 11.02 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 32.65 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -28.89 Bn |
| 10 | Medicus Pharma | 14.88 Mn | -298,205.43 | - | 10.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.84 Mn |
| Dec 31, 2025 | 9.94 Mn |
| Sep 30, 2025 | 10.66 Mn |
| Jun 30, 2025 | 8.54 Mn |
| Mar 31, 2025 | 3.34 Mn |
| Dec 31, 2024 | 2.31 Mn |
| Dec 31, 2023 | 781,609.00 |